Your browser doesn't support javascript.
loading
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
Jost, Stefanie T; Kaldenbach, Marie-Ann; Antonini, Angelo; Martinez-Martin, Pablo; Timmermann, Lars; Odin, Per; Katzenschlager, Regina; Borgohain, Rupam; Fasano, Alfonso; Stocchi, Fabrizio; Hattori, Nobutaka; Kukkle, Prashanth Lingappa; Rodríguez-Violante, Mayela; Falup-Pecurariu, Cristian; Schade, Sebastian; Petry-Schmelzer, Jan Niklas; Metta, Vinod; Weintraub, Daniel; Deuschl, Guenther; Espay, Alberto J; Tan, Eng-King; Bhidayasiri, Roongroj; Fung, Victor S C; Cardoso, Francisco; Trenkwalder, Claudia; Jenner, Peter; Ray Chaudhuri, K; Dafsari, Haidar S.
Afiliación
  • Jost ST; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kaldenbach MA; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Antonini A; Parkinson and Movement Disorders Unit, Department of Neurosciences (DNS), University of Padua, Padova, Italy.
  • Martinez-Martin P; Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
  • Timmermann L; Department of Neurology, University Hospital Giessen and Marburg, Marburg, Germany.
  • Odin P; Division of Neurology, Lund University, Lund, Sweden.
  • Katzenschlager R; Department of Neurology, Skåne University Hospital, Lund, Sweden.
  • Borgohain R; Department of Neurology, Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders at Klinik Donaustadt, Vienna, Austria.
  • Fasano A; Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India.
  • Stocchi F; Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital-University Health Network (UHN), Toronto, Ontario, Canada.
  • Hattori N; Division of Neurology, University of Toronto, Toronto, Ontario, Canada.
  • Kukkle PL; Krembil Research Institute, Toronto, Ontario, Canada.
  • Rodríguez-Violante M; Department of Parkinson's Disease & Movement Disorders Rehabilitation, Moriggia-Pelascini Hospital-Gravedona ed Uniti, Como, Italy.
  • Falup-Pecurariu C; University and Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy.
  • Schade S; Department of Neurology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
  • Petry-Schmelzer JN; Center for Parkinson's Disease and Movement Disorders, Manipal Hospital, Bangalore, India.
  • Metta V; Parkinson's Disease and Movement Disorders Clinic, Bangalore, India.
  • Weintraub D; Insituto Nacional de Neurologia y Neurocirugia, Movement Disorders Clinic, Mexico City, Mexico.
  • Deuschl G; Movement Disorder Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
  • Espay AJ; Department of Neurology, Faculty of Medicine, Transilvania University of Brașov, Brașov, Romania.
  • Tan EK; Department of Neurology, County Emergency Clinic Hospital, Brașov, Romania.
  • Bhidayasiri R; Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen, Germany.
  • Fung VSC; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Cardoso F; Parkinson Foundation International Centre of Excellence, King's College Hospital, London, United Kingdom.
  • Trenkwalder C; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.
  • Jenner P; Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Ray Chaudhuri K; Parkinson's Disease Research, Education and Clinical Center (PADRECC), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
  • Dafsari HS; Department of Neurology, University Hospital Schleswig-Holstein (UKSH), Christian-Albrechts-University Kiel, Kiel, Germany.
Mov Disord ; 38(7): 1236-1252, 2023 07.
Article en En | MEDLINE | ID: mdl-37147135
ABSTRACT

BACKGROUND:

To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as 'levodopa equivalent dose' (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed.

OBJECTIVES:

To update LED conversion formulae based on a systematic review.

METHODS:

The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency.

RESULTS:

The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon.

CONCLUSIONS:

The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non-pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Levodopa Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Levodopa Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Mov Disord Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania